Gene:
CYP2B6
cytochrome P450, family 2, subfamily B, polypeptide 6

PharmGKB contains no dosing guidelines for this gene. To report known dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this gene. To report a drug label with PGx, click here.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Position ? Drug ? Relevance ? Strength of
Evidence ?
rs2279343

To see relevance please register or sign in.

2
rs8192709

To see relevance please register or sign in.

3

Download a summary of all Clinical Annotations available.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

PharmGKB contains no genetic tests for this gene. To report genetic tests, click here.

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

Variant?
(build 132)
Alternate Names ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No Clinical Annotations available VA
rs12721646 c.646-17C>T
C/T
Intronic
No VIP available No Clinical Annotations available VA
rs12721655 CYP2B6: 415A>G, K139E, c.415A>G, g.13778500A>G, g.18079A>G, g.206456A>G, p.Lys139Glu
A > G
Missense
Lys139Glu
rs2279343 CYP2B6*4, CYP2B6:18053A>G, CYP2B6:785A>G, CYP2B6:K262R, CYP2B6:Lys262Arg, c.785A>G, g.13783481A>G, g.211437A>G, g.23060A>G, p.Lys262Arg, part of CYP2B6*6
A > G
Missense
Lys262Arg
rs28399499 CYP2B6: 983T>C, CYP2B6:Ile328Thr, I328T, c.983T>C, g.13786439T>C, g.214395T>C, g.26018T>C, p.Ile328Thr, part of CYP2B6*18
T > C
Missense
Ile328Thr
rs3211371 1459C>T, Arg487Cys, CYP2B6*5, CYP2B6*7, CYP2B6:1459C>T, CYP2B6:Arg487Cys, c.1459C>T, g.13790933C>T, g.218889C>T, g.30512C>T, p.Arg487Cys, part of CYP2B6*1C
C > T
Missense
Arg487Cys
No VIP available No Clinical Annotations available VA
rs34097093 CYP2B6*28, CYP2B61132C>T, CYP2B6:R378X, c.1132C>T, g.13786588C>T, g.214544C>T, g.26167C>T, p.Arg378X
C > T
Stop Codon
Arg378Xaa
No VIP available No Clinical Annotations available VA
rs34223104 -82, CYP2B6:, defining SNP of CYP2B6*22, g.13765347T>C, g.193303T>C, g.4926T>C
T > C
5' Flanking
No VIP available No Clinical Annotations available VA
rs35303484 c.136A>T, g.13765564A>T, g.193520A>T, g.5143A>T, p.Met46Leu
A > T
A > G
Missense
Met46Leu
No VIP available No Clinical Annotations available VA
rs35979566 c.1172T>A, g.13786816T>A, g.214772T>A, g.26395T>A, p.Ile391Asn
T > A
Missense
Ile391Asn
No VIP available No Clinical Annotations available VA
rs36079186 CYP2B6*27, CYP2B6:593T>C, CYP2B6:M198T, c.593T>C, g.13781136T>C, g.20715T>C, g.209092T>C, p.Met198Thr
T > C
Missense
Met198Thr
rs3745274 CYP2B6*6, CYP2B6:516G>T, CYP2B6:Gln172His, Q172H, c.516G>T, g.13781059G>T, g.20638G>T, g.209015G>T, p.Gln172His
G > T
Missense
Gln172His
No VIP available No Clinical Annotations available VA
rs45482602 c.777C>A, g.13783473C>A, g.211429C>A, g.23052C>A, p.Ser259Arg
C > T
C > A
Missense
Ser259Arg
No VIP available No Clinical Annotations available VA
rs58425034 c.646-159G>C, g.13783183G>C, g.211139G>C, g.22762G>C
G > C
Intronic
No VIP available CA VA
rs8192709 CYP2B6*2, CYP2B6:64C>T, c.64C>T, g.13765492C>T, g.193448C>T, g.5071C>T, p.Arg22Cys
C > T
Missense
Arg22Cys
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP build 132

Overview

Alternate Names:  cytochrome P450 2B6; cytochrome P450 IIB1; cytochrome P450, subfamily IIB (phenobarbital-inducible), polypeptide 6
Alternate Symbols:  CPB6; CYP2B; CYP2B7; CYP2B7P; CYPIIB6; IIB1; P450
Haplotypes: CYP2B6*1; CYP2B6*1A; CYP2B6*1B; CYP2B6*1C; CYP2B6*1D; CYP2B6*1E; CYP2B6*1F; CYP2B6*1G; CYP2B6*1H; CYP2B6*1J; CYP2B6*1K; CYP2B6*1L; CYP2B6*1M; CYP2B6*1N; CYP2B6*2; CYP2B6*2A; CYP2B6*2B; CYP2B6*3; CYP2B6*4; CYP2B6*4A; CYP2B6*4B; CYP2B6*4C; CYP2B6*4D; CYP2B6*5; CYP2B6*5A; CYP2B6*5B; CYP2B6*5C; CYP2B6*6; CYP2B6*6A; CYP2B6*6B; CYP2B6*6C; CYP2B6*7; CYP2B6*7A; CYP2B6*7B; CYP2B6*8; CYP2B6*9; CYP2B6*10; CYP2B6*11; CYP2B6*11A; CYP2B6*11B; CYP2B6*12; CYP2B6*13; CYP2B6*13A; CYP2B6*13B; CYP2B6*14; CYP2B6*15; CYP2B6*15A; CYP2B6*15B; CYP2B6*16; CYP2B6*17; CYP2B6*17A; CYP2B6*17B; CYP2B6*18; CYP2B6*19; CYP2B6*20; CYP2B6*21; CYP2B6*22; CYP2B6*23; CYP2B6*24; CYP2B6*25; CYP2B6*26; CYP2B6*27; CYP2B6*28; CYP2B6*29
PharmGKB Accession Id: PA123

Details

Cytogenetic Location: chr19 : q13.2 - q13.2
GP mRNA Boundary: chr19 : 41497204 - 41524301
GP Gene Boundary: chr19 : 41487204 - 41527301
Strand: plus
Product Name: No data available
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

All alleles are displayed on the positive chromosomal strand.

Download Haplotype Data (CSV)

Haplotype rs12721649 rs12721655 rs2279341 rs2279342 rs2279343 rs2279344 rs28399499 rs3211369 rs3211371 rs33926104 rs33973337 rs33980385 rs34097093 rs34223104 rs34284776 rs34698757 rs34826503 rs34883432 rs35010098 rs35266616 rs35303484 rs35468935 rs35622401 rs35773040 rs35979566 rs36056539 rs36060847 rs36079186 rs3745274 rs3826711 rs45482602 rs4802101 rs4803418 rs4803419 rs8192709 rs8192719
CYP2B6*1 G A G A/T A G T A C C A A C T G C C A C C A C G G T C G T G C C T/C C/G C/T C C
CYP2B6*1A G A G A A G T A C C A A C T G C C A C C A C G G T C G T G C C T C C C C
CYP2B6*1B G A G A A G T A C C A A C T G C C A C C A C G G T C G T G C C T C T C C
CYP2B6*1C G A G A A G T A C C A A C T G C C A C C A C G G T C G T G C C T G C C C
CYP2B6*1D G A G A A G T A C C A A C T G C C A C C A C G G T C G T G C C T C C C C
CYP2B6*1E G A G A A G T A C C A A C T G C C A C C A C G G T C G T G C C T C C C C
CYP2B6*1F G A G A A G T A C C A A C T G C C A C C A C G G T C G T G C C T C C C C
CYP2B6*1G G A G A A G T A C C A A C T G C C A C C A C G G T C G T G C C C C C C C
CYP2B6*1H G A G A A G T A C C A A C T G C C A C C A C G G T C G T G C C C C C C C
CYP2B6*1J G A G A A G T A C C A A C T G C C A C C A C G G T C G T G C C C C C C C
CYP2B6*1K G A G A A G T A C C A A C T G C C A C C A C G G T C G T G C C C C C C C
CYP2B6*1L G A G A A G T A C C A A C T G C C A C C A C G G T C G T G C C C C C C C
CYP2B6*1M G A G A A G T A C C A A C T G C C A C C A C G G T C G T G C C T C C C C
CYP2B6*1N G A G A A G T A C C A A C T G C C A C C A C G G T C G T G C C C C C C C
CYP2B6*2 G A G/C A A G T A C C A A C T G C C A C C A C G G T C G T G C C T C C T C
CYP2B6*2A G A G A A G T A C C A A C T G C C A C C A C G G T C G T G C C T C C T C
CYP2B6*2B G A C A A G T A C C A A C T G C C A C C A C G G T C G T G C C T C C T C
CYP2B6*3 G A G A A G T A C C A A C T G C C A C C A C G G T C G T G C A T C C C C
CYP2B6*4 G A G A/T G G T A C C A A C T G C C A C C A C G G T C G T G C C T/C C C C C
CYP2B6*4A G A G A G G T A C C A A C T G C C A C C A C G G T C G T G C C T C C C C
CYP2B6*4B G A G A G G T A C C A A C T G C C A C C A C G G T C G T G C C C C C C C
CYP2B6*4C G A G T G G T A C C A A C T G C C A C C A C G G T C G T G C C T C C C C
CYP2B6*4D G A G A G G T A C C A A C T G C C A C C A C G G T C G T G C C C C C C C
CYP2B6*5 G A G A A G T A T C A A C T G C C A C C A C G G T C G T G C C T/C C C C C
CYP2B6*5A G A G A A G T A T C A A C T G C C A C C A C G G T C G T G C C T C C C C
CYP2B6*5B G A G A A G T A T C A A C T G C C A C C A C G G T C G T G C C C C C C C
CYP2B6*5C G A G A A G T A T C A A C T G C C A C C A C G G T C G T G C C T C C C C
CYP2B6*6 G A G A G G T A C C A A C T G C C A C C A C G G T C G T T C C T/C C C C C
CYP2B6*6A G A G A G G T A C C A A C T G C C A C C A C G G T C G T T C C T C C C C
CYP2B6*6B G A G A G G T A C C A A C T G C C A C C A C G G T C G T T C C C C C C C
CYP2B6*6C G A G A G G T A C C A A C T G C C A C C A C G G T C G T T C C C C C C C
CYP2B6*7 G A G A G G T A T C A A C T G C C A C C A C G G T C G T T C C T/C C C C C
CYP2B6*7A G A G A G G T A T C A A C T G C C A C C A C G G T C G T T C C T C C C C
CYP2B6*7B G A G A G G T A T C A A C T G C C A C C A C G G T C G T T C C C C C C C
CYP2B6*8 G G G A A G T A C C A A C T G C C A C C A C G G T C G T G C C T C C C C
CYP2B6*9 G A G A A G T A C C A A C T G C C A C C A C G G T C G T T C C T C C C T
CYP2B6*10 G A C A A G T A C C A A C T G C C T C C A C G G T C G T G C C T C C T C
CYP2B6*11 G A G A A G/A T A C C A A C T G C C A C C G C G G T C G T G C C T C C C C
CYP2B6*11A G A G A A G T A C C A A C T G C C A C C G C G G T C G T G C C T C C C C
CYP2B6*11B G A G A A A T A C C A A C T G C C A C C G C G G T C G T G C C T C C C C
CYP2B6*12 G A G A A A T A C C A A C T G C C A C C A C G G T C A T G C C T C C C C
CYP2B6*13 G G G A G A T A C C A A C T G C C A C C A C G G T C G T T C C T C T/C C T
CYP2B6*13A G G G A G A T A C C A A C T G C C A C C A C G G T C G T T C C T C C C T
CYP2B6*13B G G G A G A T A C C A A C T G C C A C C A C G G T C G T T C C T C T C T
CYP2B6*14 G A G A A A T A C C A A C T G C C A C C A C G A T C G T G C C T C T C C
CYP2B6*15 G A G A A A/G T A C C A A C T G C C A C C A C G G A C G T G C C T C T C C
CYP2B6*15A G A G A A G T A C C A A C T G C C A C C A C G G A C G T G C C T C T C C
CYP2B6*15B G A G A A A T A C C A A C T G C C A C C A C G G A C G T G C C T C T C C
CYP2B6*16 G A G A G G C A C C A A C T G C C A C C A C G G T C G T G C C T C C C C
CYP2B6*17 G A G A A A T A C A T G C T C C C A C C A C/T G G T C G T G C C T C C C C
CYP2B6*17A G A G A A A T A C A T G C T C C C A C C A T G G T C G T G C C T C C C C
CYP2B6*17B G A G A A A T A C A T G C T C C C A C C A C G G T C G T G C C T C C C C
CYP2B6*18 A A G A A A C A C C A A C T G C C A C C A C G G T C G T G C C T C C C C
CYP2B6*19 G A G A G A T A C C A A C T G C T A C C A C G G T C G T T C C T C C C T
CYP2B6*20 G A G A G A T A C C A A C T G C C A C C A C G G T T G T T C C T C C C C
CYP2B6*21 G A G A A A T A C C A A C T G C C A A C A C G G T C G T G C C T C C C C
CYP2B6*22 G A G A A G T A C C A A C C G C C A C C A C G G T C G T G C C C C C C C
CYP2B6*23 G A G A A G T G C C A A C T G C C A C C A C G G T C G T G C C T C C C C
CYP2B6*24 G A G A A G T A C C A A C T G C C A C C A C G G T C G T G C C T C C C C
CYP2B6*25 G A G A A G T A C C A A C T G C C A C C A C G G T C G T G C C T C C C C
CYP2B6*26 G A G A G G T A C C A A C T G C C A C C A C G G T C G T T G C T C C C C
CYP2B6*27 G A G A A A T A C C A A C T G C C A C C A C G G T C G C G C C T C C C C
CYP2B6*28 A A G A A A T A C C A A T T G G C A C T A C C G T C G T G C C C C C C C
CYP2B6*29 G A G A A G T A C A T G C T C C C A C C A C G G T C G C T C C T C C C C

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Carbamazepine Pathway, Pharmacokinetics
    Stylized liver cell depicting candidate genes involved in the pharmacokinetics of carbamazepine.
  1. Clopidogrel Pathway, Pharmacokinetics
    Clopidogrel metabolism.
  1. Cyclophosphamide Pathway, Pharmacokinetics
    Model human liver cell showing genes involved in the metabolism of cyclophosphamide.
  1. Ifosfamide Pathway (PK)
    Model human liver cell showing genes involved in the metabolism of ifosfamide
  1. Nevirapine Pathway, Pharmacokinetics
    Representation of candidate genes involved in biotransformation of nevirapine and its mechanism of action in an infected liver cell.
  1. Nicotine Pathway, Pharmacokinetics
    Summary of nicotine metabolism in human liver cell.
  1. Phenytoin Pathway, Pharmacokinetics
    Genes involved in the metabolism of phenytoin in the human liver cell.
  1. Tamoxifen Pathway, Pharmacokinetics
    Tamoxifen metabolism in the liver.

External Pathways

Links to non-PharmGKB pathways.

  1. Xenobiotics - (Reactome via Pathway Interaction Database)

Curated Information ?

Evidence Gene
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
NR1I2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
NR1I3

Curated Information ?

Curated Information ?

Publications related to CYP2B6: 130

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians. Pharmacogenomics. 2012. Brown Kevin C, et al. [Article:22111602@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of drugs withdrawn from the market. Pharmacogenomics. 2012. Zhang Wei, et al. [Article:22256871@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Associations Between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 Alleles in Relation to Efavirenz and Nevirapine Pharmacokinetics in HIV-Infected Individuals. Therapeutic drug monitoring. 2012. Heil Sandra G, et al. [Article:22354160@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pharmacogenetics of toxicity, plasma trough concentration and treatment outcome with nevirapine-containing regimen in anti-retroviral-naïve HIV-infected adults: an exploratory study of the TRIANON ANRS 081 trial. Basic & clinical pharmacology & toxicology. 2011. Gozalo Claire, et al. [Article:21824325@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents. Breast cancer research and treatment. 2011. Lu Wenjie Jessie, et al. [Article:21814747@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Influence of CYP2B6 and ABCB1 SNPs on Nevirapine Plasma Concentrations in Burundese HIV-positive Patients Using Dried Sample Spot Devices. British journal of clinical pharmacology. 2011. Calcagno A, et al. [Article:22188122@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma. Clinical pharmacology and therapeutics. 2011. Mürdter T E, et al. [Article:21451508@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy. Clinical pharmacology and therapeutics. 2011. Scott S A, et al. [Article:21716271@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effect of Rifampicin and CYP2B6 Genotype on Long-Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients With or Without Tuberculosis. Clinical pharmacology and therapeutics. 2011. Ngaimisi E, et al. [Article:21814190@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine. Clinical pharmacology and therapeutics. 2011. Peltoniemi M A, et al. [Article:21716267@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapy. Clinical pharmacology and therapeutics. 2011. Sadee W, et al. [Article:21289622@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Complex Drug Interactions of HIV Protease Inhibitors 2: In Vivo Induction and In Vitro to In Vivo Correlation of Induction of Cytochrome P450 1A2, 2B6 and 2C9 by Ritonavir or Nelfinavir. Drug metabolism and disposition: the biological fate of chemicals. 2011. Kirby Brian J, et al. [Article:21930825@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effects of pregnane X receptor (NR1I2) and CYP2B6 genetic polymorphisms on the induction of bupropion hydroxylation by rifampin. Drug metabolism and disposition: the biological fate of chemicals. 2011. Chung Jae Yong, et al. [Article:20876786@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Influence of sex on propofol metabolism, a pilot study: implications for propofol anesthesia. European journal of clinical pharmacology. 2011. Loryan Irena, et al. [Article:22006347@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Smoking Cessation Pharmacogenetics: Analysis of Varenicline and Bupropion in Placebo-Controlled Clinical Trials. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2011. King David P, et al. [Article:22048466@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine. Pharmacogenetics and genomics. 2011. Lehr Thorsten, et al. [Article:21860339@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
PharmGKB summary: carbamazepine pathway. Pharmacogenetics and genomics. 2011. Thorn Caroline F, et al. [Article:21738081@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients. Pharmacogenomics. 2011. Hung Chin-Chuan, et al. [Article:21902500@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Factors influencing plasma nevirapine levels: a study in HIV-infected children on generic antiretroviral treatment in India. The Journal of antimicrobial chemotherapy. 2011. Swaminathan Soumya, et al. [Article:21393201@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. The Journal of antimicrobial chemotherapy. 2011. Schipani Alessandro, et al. [Article:21441248@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase complex. The Journal of pharmacology and experimental therapeutics. 2011. Zhang Haoming, et al. [Article:21659470@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort study. The pharmacogenomics journal. 2011. Yimer G, et al. [Article:21862974@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients. AIDS research and therapy. 2010. Gounden Verena, et al. [Article:20723261@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study. Breast cancer research : BCR. 2010. Gor Priya P, et al. [Article:20459744@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. British journal of cancer. 2010. Bray J, et al. [Article:20179710@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients. Clinical neurology and neurosurgery. 2010. Tan Lan, et al. [Article:20089352@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Breaking Barriers in the Genomics and Pharmacogenetics of Drug Addiction. Clinical pharmacology and therapeutics. 2010. Ho M K, et al. [Article:20981002@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
OPRM1 and CYP2B6 gene variants as risk factors in methadone-related deaths. Clinical pharmacology and therapeutics. 2010. Bunten H, et al. [Article:20668445@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug metabolism and disposition: the biological fate of chemicals. 2010. Kazui Miho, et al. [Article:19812348@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
In Vitro P450-Mediated Metabolism of Exemestane. Drug metabolism and disposition: the biological fate of chemicals. 2010. Kamdem Landry K, et al. [Article:20876785@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Efavirenz in the therapy of HIV infection. Expert opinion on drug metabolism & toxicology. 2010. Rakhmanina Natella Y, et al. [Article:20001610@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors. Fertility and sterility. 2010. Su H Irene, et al. [Article:19376514@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment. Human genetics. 2010. Rodriguez-Antona Cristina, et al. [Article:19823875@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. Journal of clinical pharmacology. 2010. Farid Nagy A, et al. [Article:19948947@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
Clopidogrel pathway. Pharmacogenetics and genomics. 2010. Sangkuhl Katrin, et al. [Article:20440227@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Functional characterization of 26 CYP2B6 allelic variants (CYP2B6.2-CYP2B6.28, except CYP2B6.22). Pharmacogenetics and genomics. 2010. Watanabe Takashi, et al. [Article:20517174@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB summary: very important pharmacogene information for CYP2B6. Pharmacogenetics and genomics. 2010. Thorn Caroline F, et al. [Article:20648701@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients. Pharmacogenomics. 2010. Elens Laure, et al. [Article:20860463@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique. Pharmacogenomics. 2010. Ciccacci Cinzia, et al. [Article:20017669@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Changes in the gene expression profile of gastric cancer cells in response to ibuprofen: a gene pathway analysis. The pharmacogenomics journal. 2010. Bonelli P, et al. [Article:20548326@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearance. The pharmacogenomics journal. 2010. Edvardsen H, et al. [Article:20157331@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. AIDS (London, England). 2009. Kwara Awewura, et al. [Article:19779319@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. British journal of clinical pharmacology. 2009. Kwara Awewura, et al. [Article:19371316@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa. British journal of clinical pharmacology. 2009. Ekhart Corine, et al. [Article:19076156@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4'-methanol-bisbenzonitrile in vitro. Cancer chemotherapy and pharmacology. 2009. Jeong Seongwook, et al. [Article:19198839@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation. 2009. Mega Jessica L, et al. [Article:19414633@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. Clinical pharmacology and therapeutics. 2009. Arab-Alameddine M, et al. [Article:19225447@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The relationships of ABCB1 3435C>T and CYP2B6 516G>T with high-density lipoprotein cholesterol in HIV-infected patients receiving Efavirenz. Clinical pharmacology and therapeutics. 2009. Mahungu T W, et al. [Article:19474786@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Polymorphic drug metabolism in anaesthesia. Current drug metabolism. 2009. Restrepo Juan G, et al. [Article:19442086@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6. Current drug metabolism. 2009. Mo Sui-Lin, et al. [Article:19702527@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Allele and genotype frequencies of cytochrome P450 2B6 gene in a Mongolian population. Drug metabolism and disposition: the biological fate of chemicals. 2009. Davaalkham Jagdagsuren, et al. [Article:19581387@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Decreased susceptibility of the cytochrome P450 2B6 variant K262R to inhibition by several clinically important drugs. Drug metabolism and disposition: the biological fate of chemicals. 2009. Talakad Jyothi C, et al. [Article:19074527@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Mechanism-based inhibition of human cytochrome P450 2B6 by ticlopidine, clopidogrel, and the thiolactone metabolite of prasugrel. Drug metabolism and disposition: the biological fate of chemicals. 2009. Nishiya Yumi, et al. [Article:19047469@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Methadone induces the expression of hepatic drug-metabolizing enzymes through the activation of pregnane X receptor and constitutive androstane receptor. Drug metabolism and disposition: the biological fate of chemicals. 2009. Tolson Antonia H, et al. [Article:19520773@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. European heart journal. 2009. Wallentin Lars. [Article:19633016@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. HIV medicine. 2009. Mahungu Tw, et al. [Article:19228205@PubMed]
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2009. Rocha V, et al. [Article:19005482@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenetics and genomics. 2009. di Iulio Julia, et al. [Article:19238117@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Application of pharmacogenomics to malaria: a holistic approach for successful chemotherapy. Pharmacogenomics. 2009. Mehlotra Rajeev K, et al. [Article:19290792@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti. The Journal of infectious diseases. 2009. Leger Paul, et al. [Article:19659438@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cytochrome P(450)-dependent toxic effects of primaquine on human erythrocytes. Toxicology and applied pharmacology. 2009. Ganesan Shobana, et al. [Article:19616568@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Analytical and bioanalytical chemistry. 2008. Zanger Ulrich M, et al. [Article:18695978@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical pharmacology of artemisinin-based combination therapies. Clinical pharmacokinetics. 2008. German Polina I, et al. [Article:18193915@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Current drug metabolism. 2008. Wang Hongbing, et al. [Article:18781911@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pathways of carbamazepine bioactivation in vitro. III. The role of human cytochrome P450 enzymes in the formation of 2,3-dihydroxycarbamazepine. Drug metabolism and disposition: the biological fate of chemicals. 2008. Pearce Robin E, et al. [Article:18463198@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pyrethroids: cytotoxicity and induction of CYP isoforms in human hepatocytes. Drug metabolism and drug interactions. 2008. Das Parikshit C, et al. [Article:19326768@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine. Drug metabolism and pharmacokinetics. 2008. Hagihara Katsunobu, et al. [Article:19122335@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The environmental genome project: reference polymorphisms for drug metabolism genes and genome-wide association studies. Drug metabolism reviews. 2008. Rieder Mark J, et al. [Article:18464045@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Quantitative determination of clopidogrel active metabolite in human plasma by LC-MS/MS. Journal of pharmaceutical and biomedical analysis. 2008. Takahashi Makoto, et al. [Article:18829199@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. Pharmacogenetics and genomics. 2008. Ekhart Corine, et al. [Article:18496131@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Caffeine as a marker substrate for testing cytochrome P450 activity in human and rat. Pharmacological reports : PR. 2008. Kot Marta, et al. [Article:19211970@PubMed]
Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. The Journal of antimicrobial chemotherapy. 2008. Wyen Christoph, et al. [Article:18281305@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver. The Journal of pharmacology and experimental therapeutics. 2008. Hofmann Marco H, et al. [Article:18171905@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clinical pharmacology and therapeutics. 2007. Farid N A, et al. [Article:17361128@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clinical pharmacology and therapeutics. 2007. Rotger M, et al. [Article:17235330@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Selective induction of human hepatic cytochromes P450 2B6 and 3A4 by metamizole. Clinical pharmacology and therapeutics. 2007. Saussele T, et al. [Article:17344806@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clinical pharmacology and therapeutics. 2007. Eap C B, et al. [Article:17329992@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007. Schroth Werner, et al. [Article:18024866@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effects of the flavonoid biochanin A on gene expression in primary human hepatocytes and human intestinal cells. Molecular nutrition & food research. 2007. Moon Young Jin, et al. [Article:17340576@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco. 2007. David Sean P, et al. [Article:17654295@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Gene-gene interactions between CYP2B6 and CYP2A6 in nicotine metabolism. Pharmacogenetics and genomics. 2007. Ring Huijun Z, et al. [Article:18004205@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics. 2007. Desta Zeruesenay, et al. [Article:17559344@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics. 2007. Zanger Ulrich M, et al. [Article:17638512@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacology & therapeutics. 2007. Ingelman-Sundberg Magnus, et al. [Article:18001838@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006. Hulot Jean-Sébastien, et al. [Article:16772608@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clinical pharmacology and therapeutics. 2006. Crettol Séverine, et al. [Article:17178267@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Determinants of the rate of nicotine metabolism and effects on smoking behavior. Clinical pharmacology and therapeutics. 2006. Johnstone Elaine, et al. [Article:17015050@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug metabolism and disposition: the biological fate of chemicals. 2006. Rehmel Jessica L Fayer, et al. [Article:16415119@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Bupropion: pharmacology and therapeutic applications. Expert review of neurotherapeutics. 2006. Foley Kevin F, et al. [Article:17009913@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Ketoconazole and miconazole are antagonists of the human glucocorticoid receptor: consequences on the expression and function of the constitutive androstane receptor and the pregnane X receptor. Molecular pharmacology. 2006. Duret Cedric, et al. [Article:16608920@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Stimulation of AMP-activated protein kinase is essential for the induction of drug metabolizing enzymes by phenobarbital in human and mouse liver. Molecular pharmacology. 2006. Rencurel Franck, et al. [Article:16988011@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenetics and genomics. 2006. Wang Jue, et al. [Article:16495778@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cytochrome P450s and other enzymes in drug metabolism and toxicity. The AAPS journal. 2006. Guengerich F Peter. [Article:16584116@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Overview of the pharmacogenetics of HIV therapy. The pharmacogenomics journal. 2006. Rodríguez-Nóvoa S, et al. [Article:16462814@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype. Toxicological sciences : an official journal of the Society of Toxicology. 2006. Kiang Tony K L, et al. [Article:16945988@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clinical pharmacology and therapeutics. 2005. Crettol Séverine, et al. [Article:16338275@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2A6 AND CYP2B6 are involved in nornicotine formation from nicotine in humans: interindividual differences in these contributions. Drug metabolism and disposition: the biological fate of chemicals. 2005. Yamanaka Hiroyuki, et al. [Article:16135656@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cancer treatment and pharmacogenetics of cytochrome P450 enzymes. Investigational new drugs. 2005. van Schaik Ron H N. [Article:16267627@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A natural CYP2B6 TATA box polymorphism (-82T--> C) leading to enhanced transcription and relocation of the transcriptional start site. Molecular pharmacology. 2005. Zukunft Jörg, et al. [Article:15722458@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenetics and genomics. 2005. Klein Kathrin, et al. [Article:16272958@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenetics and genomics. 2005. Rotger Margalida, et al. [Article:15864119@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. The Journal of infectious diseases. 2005. Haas David W, et al. [Article:16267764@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS (London, England). 2004. Haas David W, et al. [Article:15622315@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochemical and biophysical research communications. 2004. Tsuchiya Kiyoto, et al. [Article:15194512@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
The unique regulation of brain cytochrome P450 2 (CYP2) family enzymes by drugs and genetics. Drug metabolism reviews. 2004. Miksys Sharon, et al. [Article:15237857@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles. The Journal of pharmacology and experimental therapeutics. 2004. Lang Thomas, et al. [Article:15190123@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annual review of pharmacology and toxicology. 2003. Ding Xinxin, et al. [Article:12171978@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9. Clinical pharmacology and therapeutics. 2003. Simonsson Ulrika S H, et al. [Article:12844133@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug metabolism and disposition: the biological fate of chemicals. 2003. Madan Ajay, et al. [Article:12642468@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics. 2003. Kirchheiner Julia, et al. [Article:14515060@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. The Journal of pharmacology and experimental therapeutics. 2003. Lamba Vishal, et al. [Article:14551287@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. The Journal of pharmacology and experimental therapeutics. 2003. Ward Bryan A, et al. [Article:12676886@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. The pharmacogenomics journal. 2003. Xie H-J, et al. [Article:12629583@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism. Drug metabolism and disposition: the biological fate of chemicals. 2002. Rae James M, et al. [Article:11950782@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Molecular pharmacology. 2002. Maglich Jodi M, et al. [Article:12181440@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics. 2002. Lerman Caryn, et al. [Article:12439223@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes. The Journal of biological chemistry. 2002. Drocourt Lionel, et al. [Article:11991950@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Involvement of human liver cytochrome P4502B6 in the metabolism of propofol. British journal of clinical pharmacology. 2001. Oda Y, et al. [Article:11298076@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Calcium channel modulators of the dihydropyridine family are human pregnane X receptor activators and inducers of CYP3A, CYP2B, and CYP2C in human hepatocytes. Drug metabolism and disposition: the biological fate of chemicals. 2001. Drocourt L, et al. [Article:11560876@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics. 2001. Lang T, et al. [Article:11470993@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug metabolism and disposition: the biological fate of chemicals. 2000. Hesse L M, et al. [Article:10997936@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug metabolism and disposition: the biological fate of chemicals. 2000. Faucette S R, et al. [Article:10997944@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Archives of toxicology. 1999. Yamazaki H, et al. [Article:10350185@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin. British journal of clinical pharmacology. 1999. Svensson U S, et al. [Article:10583023@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Metabolism of beta-arteether to dihydroqinghaosu by human liver microsomes and recombinant cytochrome P450. Drug metabolism and disposition: the biological fate of chemicals. 1998. Grace J M, et al. [Article:9531517@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer research. 1997. Chang T K, et al. [Article:9157990@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug metabolism and disposition: the biological fate of chemicals. 1997. Code E L, et al. [Article:9280407@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Molecular pharmacology. 1994. Relling M V, et al. [Article:8114683@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. The Journal of pharmacology and experimental therapeutics. 1994. Shimada T, et al. [Article:8035341@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer research. 1993. Chang T K, et al. [Article:8242617@PubMed]
PharmGKB® is a registered trademark of HHS and is financially supported by NIH/NIGMS. It is managed at Stanford University (R24 GM61374).
©2001-2012 PharmGKB.